Vland on the "2026 List of Top 500 Private Enterprises by Invention Patents"

‍‍‍‍

On September 9, the All-China Federation of Industry and Commerce released the "2026 List of Top 500 Private Enterprises by Invention Patents." Qingdao Vland Biotech Inc. ranked 247th overall and 15th among the 32 private enterprises from Shandong Province that made the list. This marks the fourth consecutive year since 2023 that Vland has been included in this ranking.

Technological innovation is the core driver of Vland's growth. The company steadfastly adheres to a philosophy of independent innovation; its R&D investment totaled RMB 139 million in 2025, with cumulative R&D spending reaching approximately RMB 944 million over the past decade. In the first half of 2026, R&D investment amounted to RMB 62.0338 million, representing 8.74% of operating revenue—a high level within the industry.

The company has established six major technology centers and two key laboratories, conducting R&D activities supported by eight national-level innovation platforms. It employs a "Dual-Lead System + Product Manager" R&D management model and utilizes a management platform based on the Integrated Product Development (IPD) system to manage the R&D process, carrying out applied research and product promotion across multiple fields.

In the first half of 2026, Vland secured 30 new domestic invention patents and three granted US patents. As of the end of the reporting period, the company and its subsidiaries held 446 valid domestic invention patents, 13 valid US patents, four valid European patents, and 28 PCT applications, alongside 60 new veterinary drug registration certificates (including three for Class I China national new veterinary drugs).

‍‍‍‍